In addition, in some histologies (e.g., HER2-positive breast cancer), neoadjuvant TT plus chemotherapy has been associated with a higher rate of pCR and better survival outcomes compared to neoadjuvant chemotherapy alone [112]. Here, ERBB2 is linked to breast cancer.